CLCS (Cell Source) Pretax Margin %: % (As of Dec. 2024)


CLCS Cell Source Inc CLCS
35 GF Score
Price $0.75
View Full Analysis

What is Cell Source Pretax Margin %?

Cell Source CLCS -9.64% 35 Pretax Margin % is % as of Dec. 2024. GuruFocus rates CLCS with a GF Score™ of 35/100.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Cell Source's Pre-Tax Income for the three months ended in Dec. 2024 was $-0.33 Mil. Cell Source's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Cell Source's pretax margin for the quarter that ended in Dec. 2024 was %.

The historical rank and industry rank for Cell Source's Pretax Margin % or its related term are showing as below:


CLCS's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.63
* Ranked among companies with meaningful Pretax Margin % only.

Cell Source  (OTCPK:CLCS) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Cell Source Pretax Margin % Related Terms

Cell Source Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Cell Source's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source Pretax Margin % Chart

Cell Source Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cell Source Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CLCS vs EDSA, CTXR, ASBP: Pretax Margin % Comparison

For the Biotechnology subindustry, Cell Source's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Source Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Cell Source's Pretax Margin % falls into.


CLCS
35GF Score
Cell Source Inc CLCS
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Cell Source's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-4.513/0
= %

Cell Source's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-0.331/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Cell Source (CLCS) has a Pretax Margin % of % as of Dec. 2024. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cell Source and its competitors.
Is Cell Source's Pretax Margin % too high?
Cell Source's current Pretax Margin % is %. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's Pretax Margin % compare to EDSA and CTXR?
Cell Source's Pretax Margin % of % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cell Source and its competitors. Cell Source's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current Pretax Margin % of %. The current Pretax Margin % is %. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Cell Source (CLCS), the current Pretax Margin % is % as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price